DaVita/$DVA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About DaVita
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.
Ticker
$DVA
Sector
Primary listing
NYSE
Employees
76,000
Headquarters
Website
DaVita Metrics
BasicAdvanced
$8.9B
12.16
$10.20
1.12
-
Price and volume
Market cap
$8.9B
Beta
1.12
52-week high
$179.60
52-week low
$123.13
Average daily volume
761K
Financial strength
Current ratio
1.393
Quick ratio
1.276
Long term debt to equity
785.802
Total debt to equity
825.189
Interest coverage (TTM)
3.25%
Profitability
EBITDA (TTM)
2,687.971
Gross margin (TTM)
32.54%
Net profit margin (TTM)
6.35%
Operating margin (TTM)
15.01%
Effective tax rate (TTM)
20.10%
Revenue per employee (TTM)
$170,000
Management effectiveness
Return on assets (TTM)
7.15%
Return on equity (TTM)
57.94%
Valuation
Price to earnings (TTM)
12.16
Price to revenue (TTM)
0.755
Price to book
-24.9
Price to tangible book (TTM)
-1.14
Price to free cash flow (TTM)
7.714
Free cash flow yield (TTM)
12.96%
Free cash flow per share (TTM)
16.074
Growth
Revenue change (TTM)
5.09%
Earnings per share change (TTM)
8.72%
3-year revenue growth (CAGR)
4.22%
10-year revenue growth (CAGR)
-0.10%
3-year earnings per share growth (CAGR)
8.08%
10-year earnings per share growth (CAGR)
17.30%
What the Analysts think about DaVita
Analyst ratings (Buy, Hold, Sell) for DaVita stock.
Bulls say / Bears say
DaVita reported adjusted Q2 2025 earnings per share of $2.95, surpassing the Zacks consensus of $2.70 and topping Wall Street expectations, underscoring strong profit delivery (AP).
Second-quarter revenue rose 6.1% year-over-year to $3.38 billion, exceeding analyst estimates of $3.355 billion, reflecting robust demand in its core dialysis services business (Nasdaq).
Gross profit margin expanded by 31 basis points to 33.1% in Q2 2025, demonstrating operational leverage and effective cost management across the network (Nasdaq).
Mandated repurchases and capital structure actions have left DaVita with net debt of approximately $9.52 billion at the end of Q2 2025, which may constrain financial flexibility amid rising interest rates (Nasdaq).
General and administrative expenses climbed 12.2% year-over-year to $412.8 million in Q2 2025, indicating mounting cost pressures that could squeeze margins (Nasdaq).
DaVita and Fresenius Medical face a proposed class action antitrust lawsuit alleging they conspired to inflate dialysis treatment costs through anti-competitive practices, potentially exposing DaVita to significant litigation liabilities (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2025.
DaVita Financial Performance
Revenues and expenses
DaVita Earnings Performance
Company profitability
DaVita News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for DaVita stock?
DaVita (DVA) has a market cap of $8.9B as of October 14, 2025.
What is the P/E ratio for DaVita stock?
The price to earnings (P/E) ratio for DaVita (DVA) stock is 12.16 as of October 14, 2025.
Does DaVita stock pay dividends?
No, DaVita (DVA) stock does not pay dividends to its shareholders as of October 14, 2025.
When is the next DaVita dividend payment date?
DaVita (DVA) stock does not pay dividends to its shareholders.
What is the beta indicator for DaVita?
DaVita (DVA) has a beta rating of 1.12. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.